Drug Combination Prevents Clots Without Increasing Bleeding in Mouse Models

Researchers continue to hone in on how best to prevent blood clots, which cause strokes and heart attacks, without unintended side effects.

3:18 PM

Author | Haley Otman

drawing in blue ink of pills on lined paper with yellow badge on bottom right that says lab note
Credit: Michigan Medicine

A new approach to preventing blood clots, and thus more serious cardiovascular events like stroke, was successful in mouse models without causing major bleeding events.

"It's the only selective inhibitor to block activation of 12-lipoxygenase in the human platelet and prevent blood clots from forming," says study author Michael Holinstat, Ph.D., an associate professor of pharmacology, internal medicine and surgery at Michigan Medicine.

The researchers delivered the new drug, which they call ML355, by combining it with synthetic high density lipoprotein, or sHDL, for this proof-of-concept investigation. First, they tested this in human blood, and then in mouse models. The combination allowed for more precision than most of the antithrombotics currently available.

"We were able to potently and selectively target regions of inflammation and injury in the blood vessel in order to prevent blood clots and thrombosis from occurring," Holinstat says. "The millions of people with cardiovascular disease in the U.S. would benefit greatly from a lower-risk option to avoid thrombosis."

Holinstat adds that this discovery was successfully translated from identification of a critical target in the platelet regulating thrombosis to clinical trials, recently receiving orphan drug designation from the U.S. Food and Drug Administration for prophylactic treatment of heparin-induced thrombocytopenia (HIT). The FDA approved the Investigational New Drug application, and ML355 will begin clinical trials for novel treatment of patients suspected of HIT in March.

Disclosure: ML355 is licensed by Veralox Therapeutics as VLX-1005. Holinstat is a shareholder in Veralox Therapeutics. He also invented ML355 (U.S. patent no. US10,266,488; Japan patent no. 6463366).

Paper cited: "Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice," Science Advances. DOI: 10.1126/sciadv.abd0130

More Articles About: Lab Notes stroke Deep Vein Thrombosis (DVT) Stroke Prevention Heart Attack Treatment Drug Discovery Basic Science and Laboratory Research Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories supar molecule teal blue yellow red
Health Lab
Immune protein suPAR links viral infection as possible cause of kidney disease
Through a series of experiments in non-human primates, mice and humans, a multi-institutional team led by researchers from Michigan Medicine and Rush University found that the immune protein soluble urokinase plasminogen activator receptor, or suPAR, is an important link between viral infections and proteinuria; the elevation of protein in the urine is known to cause glomerulopathy, a common form of kidney disease.
doctor with patient white and black patient ignored
Health Lab
Fixing racial inequities in lupus care
When it comes to lupus care, Black adults are normally left behind despite being one of the highest lupus populations.
heart organ yellow blue
Health Lab
Irregular heartbeat after valve surgery increases risk of stroke, death
Postoperative atrial fibrillation, commonly known as Afib, has traditionally been viewed as benign and limited. But a study led by researchers at the University of Michigan Health Frankel Cardiovascular Center finds that postoperative atrial fibrillation increases the risk of strokes and permanent Afib — and is linked to worse long term survival — after heart valve surgery.
human organ for transplant
Health Lab
Findings shed light on how a pediatric heart surgery complication impacts heart transplant survival
Patients who experience this condition following the Fontan continue to have a high risk of death from the time they’re waitlisted for a new heart through receiving the transplant, according to a 20-center study led by Michigan Medicine. And one specific complication called cyanosis – or experiencing less than normal oxygen blood levels – was associated with worsened survival.
Health Lab
Managing scleroderma symptoms through a team approach
Research published in the Arthritis Care and Research Journal from Michigan Medicine found that scleroderma patients made significant strides when working with trained peer health coaches in adhering to wellness routines, leading to resilience and improvements in fatigue, pain and depressive symptoms.
grey needle into cell blue
Health Lab
Mouse model of gender-affirming testosterone treatment and fertility finds decrease in egg yield but not quality
The current IVF recommendation is for transgender patients to stop taking gender-affirming hormones before the procedure, which can be costly and life changing. Now, a team of researchers are diving in further to investigate what the best recommendations should be based on more evidence.